Actualités

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Novavax (NVAX) concluded the recent trading session at $9.59, signifying a +1.36% move from its prior day's close.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 16.3% over the past six months, topping the S&P 500 by 7 percentage points.

In the closing of the recent trading day, Novavax (NVAX) stood at $8.9, denoting a -1.17% move from the preceding trading day.

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax (NVAX) closed the most recent trading day at $9.13, moving 3.89% from the previous trading session.

Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. The move pushes Moderna stock to +94% year to date (YTD), easily the best performance in the major vaccine cohort. By comparison, Pfizer (NYSE:PFE) stock is ... Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Novavax (NASDAQ:NVAX) and its peers.

Novavax (NVAX) closed the most recent trading day at $8.88, moving 1.66% from the previous trading session.

Novavax has transferred commercialization of its COVID-19 vaccine in Europe to Sanofi. The company is shifting focus to monetizing its Matrix-M adjuvant through partnerships and licensing. These moves mark a change in how Novavax plans to generate revenue beyond direct vaccine sales. Novavax (NasdaqGS:NVAX) is repositioning itself around its vaccine technology rather than relying mainly on direct product sales. The stock trades at $8.56, with the share price up 20.1% year to date and up...

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 11.3% in the afternoon session after documents revealed that advisers to the U.S. Food and Drug Administration (FDA) will weigh updating the 2026-27 COVID-19 vaccines to target the latest circulating XFG subvariant.

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novavax has had an impressive run over the past six months as its shares have beaten the S&P 500 by 27.6%. The stock now trades at $9.21, marking a 37.6% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

Why Novavax Stock Is Back on Investor Radars Novavax (NVAX) has been catching investor attention again after recent trading swings, with the stock closing at US$9.06 and showing mixed short term performance over the past week and month. See our latest analysis for Novavax. Short term momentum has cooled, with the share price down 3.10% over one day and 4.63% over seven days. However, the stock still shows a 27.07% year to date share price return and a 17.05% total shareholder return over one...

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years.

Novavax delivered first quarter results that surpassed Wall Street’s revenue and earnings estimates, leading to a significant positive market reaction. Management attributed the quarter’s performance to strong partner-driven revenue streams, particularly from milestone payments and supply sales tied to agreements with Sanofi and Pfizer. CEO John Jacobs emphasized the shift from direct commercial activity to a strategy anchored by licensing and collaboration, noting, “We now have either licensing

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 12.3% in the afternoon session after the company reported better-than-expected first-quarter 2026 results.

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

In early May 2026, Novavax reported first-quarter revenue of US$139.51 million versus US$666.66 million a year earlier, swinging from net income of US$518.65 million to a net loss of US$9.49 million and posting basic and diluted loss per share of US$0.06 from continuing operations. Despite the year-on-year drop in sales and profitability, Novavax’s quarterly results exceeded market expectations and were underpinned by new Matrix-M licensing activity, including an upfront US$30 million...

Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

Market Catalysts Host Julie Hyman and Yahoo Finance Senior Reporter Brooke DiPalma track several of the day's top trending stock tickers, including memory chip stocks Micron Technology (MU), Intel (INTC), and Qualcomm (QCOM) opening at record highs; shares of Moderna (MRNA) and Novavax (NVAX) reacting to concerns around the hantavirus; and Constellation Energy (CEG) affirming its full-year guidance after beating first quarter earnings estimates.

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 run for the mRNA pioneer. The rally is outpacing fellow vaccine names Pfizer (NYSE:PFE), up 2% near $26.10, and Novavax (NASDAQ:NVAX), basically flat ... Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Although a better-than-expected Q1 earnings print has NVAX stock skyrocketing recently, there’s a high risk in chasing this biotech play.

The U.S. health department said one passenger on a repatriation flight has tested mildly positive for the virus, while another is currently experiencing mild symptoms.

Novavax's shares rise 16% after Q1 earnings beat estimates as the company expands Matrix-M partnerships across oncology and infectious diseases.

Companies in The News Are: DIS,NVAX,MAR,BWA